Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

75.0%

3 terminated/withdrawn out of 4 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02243124Phase 1Terminated

A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)

Role: lead

NCT00967512Phase 2Withdrawn

Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course

Role: lead

NCT00074737Phase 2Completed

Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML

Role: lead

NCT00636155Phase 2Terminated

EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Role: collaborator

All 4 trials loaded